#checkpoint inhibitor

Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.

Imjudo plus Imfinzi improved overall survival compared with standard targeted therapy for hepatocellular carcinoma.

Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

Sintilimab plus chemotherapy infused into a liver artery may offer the chance for a cure.

Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.

Nearly half of patients treated with the combination saw their tumors shrink in an early study.

The immunotherapy and targeted therapy combo improved both overall survival and patient-reported outcomes.

A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.

Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.

Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.

Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.

Seventy percent of liver cancer patients had either a partial response or stable disease.

A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.

Half of people with worse liver function responded well to immunotherapy.